BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

Abstract excerpt

BRAF mutations have been identified as targetable, oncogenic mutations in many cancers. Given the paucity of treatments for primary brain tumors and the poor prognosis associated with high-grade gliomas, BRAF mutations in glioma are of considerable interest. In this review, we present the spectrum of BRAF mutations and fusion alterations present in each class of primary brain tumor based on publicly available...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Glioma Diagnosis and Treatment
• Share to Melanoma and MAPK Pathways